Clinical Trial Update: MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist [Phase 3]

View source ↗

Summary

Phase 3 MOTION trial of safinamide as add-on to dopamine agonist in early idiopathic Parkinson's disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Parkinson Disease

Drugs mentioned

• Safinamide (Safinamide)

Snippet

Sponsor: Newron Pharmaceuticals SPA | Conditions: Idiopathic Parkinson's Disease | Phase 3 | Status: COMPLETED